MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Arvinas Inc

Suletud

SektorTervishoid

7 -0.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.81

Max

7.34

Põhinäitajad

By Trading Economics

Sissetulek

4.1M

-45M

Müük

-43M

59M

Aktsiakasum

-0.63

Kasumimarginaal

-76.182

Töötajad

430

EBITDA

3.7M

-57M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+382.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. mai 2025

Turustatistika

By TradingEconomics

Turukapital

522M

Eelmine avamishind

7.28

Eelmine sulgemishind

7

Uudiste sentiment

By Acuity

72%

28%

338 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Arvinas Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. apr 2024, 11:42 UTC

Omandamised, ülevõtmised, äriostud

Arvinas, Novartis in ARV-766 Prostate Cancer License Pact

Võrdlus sarnastega

Hinnamuutus

Arvinas Inc Prognoos

Hinnasiht

By TipRanks

382.34% tõus

12 kuu keskmine prognoos

Keskmine 33.86 USD  382.34%

Kõrge 81 USD

Madal 10 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Arvinas Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

12

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.88 / 8.13Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

338 / 386 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.